RU2012111695A - Фторзамещенные производные 3,5- дициано-4-(1н-индазол-5-ил) -2, 6-диметил-1,4-дигидропиридина и способы их применения - Google Patents
Фторзамещенные производные 3,5- дициано-4-(1н-индазол-5-ил) -2, 6-диметил-1,4-дигидропиридина и способы их применения Download PDFInfo
- Publication number
- RU2012111695A RU2012111695A RU2012111695/04A RU2012111695A RU2012111695A RU 2012111695 A RU2012111695 A RU 2012111695A RU 2012111695/04 A RU2012111695/04 A RU 2012111695/04A RU 2012111695 A RU2012111695 A RU 2012111695A RU 2012111695 A RU2012111695 A RU 2012111695A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- formula
- compound
- dicarbonitrile
- dihydropyridin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- -1 Fluoro-substituted 3,5-dicyano-4- (1H-indazole-5-yl) -2, 6-dimethyl-1,4-dihydropyridine Chemical class 0.000 title claims 4
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 20
- 239000001257 hydrogen Substances 0.000 claims abstract 20
- 239000012453 solvate Substances 0.000 claims abstract 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910052731 fluorine Chemical group 0.000 claims abstract 8
- 239000011737 fluorine Chemical group 0.000 claims abstract 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims abstract 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 4
- UYZFYANYSIVDGM-OAHLLOKOSA-N (4r)-2-(difluoromethyl)-4-(6-fluoro-3-methyl-2h-indazol-5-yl)-6-methyl-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC(F)=C1[C@@H]1C(C#N)=C(C)NC(C(F)F)=C1C#N UYZFYANYSIVDGM-OAHLLOKOSA-N 0.000 claims abstract 2
- HWKMGVPKZQVMJQ-OAHLLOKOSA-N (4r)-2-methyl-4-(3-methyl-2h-indazol-5-yl)-6-(trifluoromethyl)-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC=C1[C@@H]1C(C#N)=C(C)NC(C(F)(F)F)=C1C#N HWKMGVPKZQVMJQ-OAHLLOKOSA-N 0.000 claims abstract 2
- HWKMGVPKZQVMJQ-HNNXBMFYSA-N (4s)-2-methyl-4-(3-methyl-2h-indazol-5-yl)-6-(trifluoromethyl)-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC=C1[C@H]1C(C#N)=C(C)NC(C(F)(F)F)=C1C#N HWKMGVPKZQVMJQ-HNNXBMFYSA-N 0.000 claims abstract 2
- MCTXOYZRWZOYKI-UHFFFAOYSA-N 2,6-bis(difluoromethyl)-4-(3-methyl-2h-indazol-5-yl)-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC=C1C1C(C#N)=C(C(F)F)NC(C(F)F)=C1C#N MCTXOYZRWZOYKI-UHFFFAOYSA-N 0.000 claims abstract 2
- WOWAGKXGSRDYJG-UHFFFAOYSA-N 2,6-bis(difluoromethyl)-4-(6-fluoro-3-methyl-2h-indazol-5-yl)-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC(F)=C1C1C(C#N)=C(C(F)F)NC(C(F)F)=C1C#N WOWAGKXGSRDYJG-UHFFFAOYSA-N 0.000 claims abstract 2
- UYZFYANYSIVDGM-UHFFFAOYSA-N 2-(difluoromethyl)-4-(6-fluoro-3-methyl-2h-indazol-5-yl)-6-methyl-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC(F)=C1C1C(C#N)=C(C)NC(C(F)F)=C1C#N UYZFYANYSIVDGM-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UYZFYANYSIVDGM-HNNXBMFYSA-N (4s)-2-(difluoromethyl)-4-(6-fluoro-3-methyl-2h-indazol-5-yl)-6-methyl-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC(F)=C1[C@H]1C(C#N)=C(C)NC(C(F)F)=C1C#N UYZFYANYSIVDGM-HNNXBMFYSA-N 0.000 claims 1
- HWKMGVPKZQVMJQ-UHFFFAOYSA-N 2-methyl-4-(3-methyl-2h-indazol-5-yl)-6-(trifluoromethyl)-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound C1=C2C(C)=NNC2=CC=C1C1C(C#N)=C(C)NC(C(F)(F)F)=C1C#N HWKMGVPKZQVMJQ-UHFFFAOYSA-N 0.000 claims 1
- FJWSHEFNTXMEOH-UHFFFAOYSA-N 4-(6-fluoro-1h-indazol-5-yl)-2-methyl-6-(trifluoromethyl)-1,4-dihydropyridine-3,5-dicarbonitrile Chemical compound N#CC1=C(C(F)(F)F)NC(C)=C(C#N)C1C(C(=C1)F)=CC2=C1NN=C2 FJWSHEFNTXMEOH-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims 1
- 239000005695 Ammonium acetate Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 125000005219 aminonitrile group Chemical group 0.000 claims 1
- 229940043376 ammonium acetate Drugs 0.000 claims 1
- 235000019257 ammonium acetate Nutrition 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 0 Cc1c([C@@](C(C#N)=*C(*)(*)*)C(C#N)=C(*)[N-])cc(c(*)n[n]2)c2c1 Chemical compound Cc1c([C@@](C(C#N)=*C(*)(*)*)C(C#N)=C(*)[N-])cc(c(*)n[n]2)c2c1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172304 | 2009-10-06 | ||
| EP09172304.9 | 2009-10-06 | ||
| PCT/EP2010/064648 WO2011042368A1 (en) | 2009-10-06 | 2010-10-01 | Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012111695A true RU2012111695A (ru) | 2013-10-10 |
Family
ID=43357944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012111695/04A RU2012111695A (ru) | 2009-10-06 | 2010-10-01 | Фторзамещенные производные 3,5- дициано-4-(1н-индазол-5-ил) -2, 6-диметил-1,4-дигидропиридина и способы их применения |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9422263B2 (enExample) |
| EP (1) | EP2485726B1 (enExample) |
| JP (1) | JP5753175B2 (enExample) |
| KR (1) | KR20120091005A (enExample) |
| CN (1) | CN102573838B (enExample) |
| AR (1) | AR078486A1 (enExample) |
| AU (1) | AU2010305550A1 (enExample) |
| BR (1) | BR112012006842A2 (enExample) |
| CA (1) | CA2773676C (enExample) |
| CL (1) | CL2012000753A1 (enExample) |
| CR (1) | CR20120150A (enExample) |
| CU (1) | CU20120051A7 (enExample) |
| DO (1) | DOP2012000085A (enExample) |
| EC (1) | ECSP12011748A (enExample) |
| ES (1) | ES2458117T3 (enExample) |
| IL (1) | IL218415A0 (enExample) |
| IN (1) | IN2012DN02675A (enExample) |
| MX (1) | MX2012003603A (enExample) |
| NZ (1) | NZ599006A (enExample) |
| PE (1) | PE20121392A1 (enExample) |
| PH (1) | PH12012500640A1 (enExample) |
| RU (1) | RU2012111695A (enExample) |
| SG (1) | SG178990A1 (enExample) |
| TW (1) | TW201124396A (enExample) |
| UY (1) | UY32922A (enExample) |
| WO (1) | WO2011042368A1 (enExample) |
| ZA (1) | ZA201201524B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2836662C2 (ru) * | 2019-02-11 | 2025-03-18 | Мерк Патент Гмбх | Индазолилизоксазольные производные для лечения заболеваний, таких как злокачественное новообразование |
| US12486260B2 (en) | 2019-02-11 | 2025-12-02 | Merck Patent Gmbh | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0650179Y2 (ja) | 1989-06-01 | 1994-12-21 | 株式会社プラコー | ブロー成形機用のダイヘッド |
| JPH0756186Y2 (ja) | 1989-07-24 | 1995-12-25 | 株式会社日本製鋼所 | パリソンの押出成形装置 |
| JP2781376B2 (ja) | 1996-06-17 | 1998-07-30 | エクセル株式会社 | 中空成形品 |
| DE102009056886A1 (de) * | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635977A (en) | 1969-11-03 | 1972-01-18 | American Cyanamid Co | Certain 6-trifluoromethylcytosines and thiocytosines their synthesis and their use in the synthesis of uracisls and thiouracil |
| ES2077591T3 (es) | 1989-01-26 | 1995-12-01 | Bayer Ag | Derivados de acido (met)acrilico opticamente activos, su fabricacion, su polimerizacion para dar polimeros opticamente activos y su uso. |
| DE19546136A1 (de) | 1995-12-11 | 1997-06-12 | Bayer Ag | Chirale stationäre Phasen für die chromatographische Trennung von optischen Isomeren |
| WO2003101968A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US20070185152A1 (en) | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| WO2005084672A1 (de) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| MX2007007102A (es) | 2004-12-13 | 2007-08-08 | Irm Llc | Compuestos y composiciones como moduladores de los receptores esteroideos y de las actividades del canal de calcio. |
| WO2006074419A2 (en) | 2005-01-07 | 2006-07-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
| CN101193637A (zh) * | 2005-01-19 | 2008-06-04 | 默克公司 | 作为有丝分裂驱动蛋白抑制剂的氟化氨基烷基-4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物 |
| JP2010513231A (ja) * | 2006-12-14 | 2010-04-30 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | たんぱく質キナーゼインヒビターとして有用なジヒドロピリジン誘導体 |
-
2010
- 2010-09-30 UY UY0001032922A patent/UY32922A/es not_active Application Discontinuation
- 2010-10-01 ES ES10760348.2T patent/ES2458117T3/es active Active
- 2010-10-01 AU AU2010305550A patent/AU2010305550A1/en not_active Abandoned
- 2010-10-01 PH PH1/2012/500640A patent/PH12012500640A1/en unknown
- 2010-10-01 RU RU2012111695/04A patent/RU2012111695A/ru not_active Application Discontinuation
- 2010-10-01 EP EP10760348.2A patent/EP2485726B1/en not_active Not-in-force
- 2010-10-01 MX MX2012003603A patent/MX2012003603A/es not_active Application Discontinuation
- 2010-10-01 KR KR1020127007824A patent/KR20120091005A/ko not_active Withdrawn
- 2010-10-01 SG SG2012015400A patent/SG178990A1/en unknown
- 2010-10-01 IN IN2675DEN2012 patent/IN2012DN02675A/en unknown
- 2010-10-01 JP JP2012532550A patent/JP5753175B2/ja not_active Expired - Fee Related
- 2010-10-01 US US13/496,722 patent/US9422263B2/en not_active Expired - Fee Related
- 2010-10-01 CN CN201080043306.5A patent/CN102573838B/zh not_active Expired - Fee Related
- 2010-10-01 NZ NZ599006A patent/NZ599006A/xx not_active IP Right Cessation
- 2010-10-01 CA CA2773676A patent/CA2773676C/en not_active Expired - Fee Related
- 2010-10-01 BR BR112012006842A patent/BR112012006842A2/pt not_active Application Discontinuation
- 2010-10-01 PE PE2012000384A patent/PE20121392A1/es not_active Application Discontinuation
- 2010-10-01 WO PCT/EP2010/064648 patent/WO2011042368A1/en not_active Ceased
- 2010-10-01 AR ARP100103574A patent/AR078486A1/es unknown
- 2010-10-05 TW TW099133784A patent/TW201124396A/zh unknown
-
2012
- 2012-02-29 ZA ZA2012/01524A patent/ZA201201524B/en unknown
- 2012-03-01 IL IL218415A patent/IL218415A0/en unknown
- 2012-03-26 CL CL2012000753A patent/CL2012000753A1/es unknown
- 2012-03-26 CU CU20120051A patent/CU20120051A7/es unknown
- 2012-03-27 EC ECSP12011748 patent/ECSP12011748A/es unknown
- 2012-03-27 CR CR20120150A patent/CR20120150A/es unknown
- 2012-03-27 DO DO2012000085A patent/DOP2012000085A/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2836662C2 (ru) * | 2019-02-11 | 2025-03-18 | Мерк Патент Гмбх | Индазолилизоксазольные производные для лечения заболеваний, таких как злокачественное новообразование |
| US12486260B2 (en) | 2019-02-11 | 2025-12-02 | Merck Patent Gmbh | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120091005A (ko) | 2012-08-17 |
| US20120264785A1 (en) | 2012-10-18 |
| BR112012006842A2 (pt) | 2016-06-07 |
| CN102573838B (zh) | 2014-09-24 |
| PE20121392A1 (es) | 2012-10-14 |
| UY32922A (es) | 2011-04-29 |
| AR078486A1 (es) | 2011-11-09 |
| SG178990A1 (en) | 2012-04-27 |
| CR20120150A (es) | 2012-08-03 |
| IL218415A0 (en) | 2012-04-30 |
| IN2012DN02675A (enExample) | 2015-09-04 |
| JP2013506699A (ja) | 2013-02-28 |
| US9422263B2 (en) | 2016-08-23 |
| ZA201201524B (en) | 2013-05-29 |
| PH12012500640A1 (en) | 2012-11-12 |
| ECSP12011748A (es) | 2012-05-30 |
| CU20120051A7 (es) | 2012-06-29 |
| EP2485726B1 (en) | 2014-03-12 |
| JP5753175B2 (ja) | 2015-07-22 |
| EP2485726A1 (en) | 2012-08-15 |
| AU2010305550A1 (en) | 2012-03-29 |
| CL2012000753A1 (es) | 2012-09-14 |
| CA2773676A1 (en) | 2011-04-14 |
| ES2458117T3 (es) | 2014-04-30 |
| CA2773676C (en) | 2017-07-04 |
| NZ599006A (en) | 2013-11-29 |
| WO2011042368A1 (en) | 2011-04-14 |
| TW201124396A (en) | 2011-07-16 |
| HK1172835A1 (en) | 2013-05-03 |
| MX2012003603A (es) | 2012-04-20 |
| DOP2012000085A (es) | 2012-07-15 |
| CN102573838A (zh) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101985778B1 (ko) | (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조 | |
| KR102117982B1 (ko) | 암 치료용 병용 요법 | |
| JP7576587B2 (ja) | Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 | |
| JP2023109922A (ja) | 癌を治療する方法 | |
| JP2023126957A (ja) | 癌を処置するための併用療法 | |
| JP4342181B2 (ja) | スピロピラゾール化合物 | |
| RU2012111695A (ru) | Фторзамещенные производные 3,5- дициано-4-(1н-индазол-5-ил) -2, 6-диметил-1,4-дигидропиридина и способы их применения | |
| JP6043733B2 (ja) | カンナビノイド受容体モジュレーター | |
| SK285231B6 (sk) | Použitie 6-[(imidazol-5-yl)metyl]chinolínovej zlúčeniny na prípravu farmaceutickej kompozície na liečbu artropatie | |
| JP2018184452A (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| JP2024001203A (ja) | 癌を処置するための併用療法 | |
| JP2019521988A (ja) | 癌を処置するためのｅｚｈ２阻害剤 | |
| ES2881048T3 (es) | Bisaminoquinolinas asimétricas y bisaminoquinolinas con enlazadores variados como inhibidores de la autofagia para el cáncer y otras terapias | |
| JP2016517434A (ja) | 癌を処置するための併用療法 | |
| RS62133B1 (sr) | Tetrahidro-1h-pirido[3,4-b]indol antiestrogeni lekovi | |
| JP2017513883A (ja) | ４−アミノ−イミダゾキノリン化合物 | |
| JP2016523935A (ja) | 治療活性化合物およびその使用方法 | |
| WO2021076688A1 (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases | |
| JP2020500872A (ja) | 癌を処置するための併用療法 | |
| JP2017525765A (ja) | 新規イミノニトリル誘導体 | |
| WO2023156453A1 (en) | Phenethylamine derivatives, compositions, and methods of use | |
| CN105085482A (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| TW201343629A (zh) | 可作為ｍｏｇａｔ－２抑制劑之新穎芐磺醯胺衍生物 | |
| EP4028008A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| RU2014118490A (ru) | Лечение фармакологически индуцированной гипохлоргидрии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20131002 |